185 related articles for article (PubMed ID: 35131090)
1. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.
Martin V; Nagy AJ; Janelidze M; Giorgadze G; Hirman J; Cady R; Mehta L; Buse DC
Clin Ther; 2022 Mar; 44(3):389-402. PubMed ID: 35131090
[TBL] [Abstract][Full Text] [Related]
2. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
Silberstein S; Diamond M; Hindiyeh NA; Biondi DM; Cady R; Hirman J; Allan B; Pederson S; Schaeffler B; Smith J
J Headache Pain; 2020 Oct; 21(1):120. PubMed ID: 33023473
[TBL] [Abstract][Full Text] [Related]
3. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
[TBL] [Abstract][Full Text] [Related]
4. Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
Apelian R; Boyle L; Hirman J; Asher D
J Headache Pain; 2022 Apr; 23(1):48. PubMed ID: 35436857
[TBL] [Abstract][Full Text] [Related]
5. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Ashina M; Saper J; Cady R; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Smith J
Cephalalgia; 2020 Mar; 40(3):241-254. PubMed ID: 32075406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
Ashina M; McAllister P; Cady R; Hirman J; Ettrup A
Cephalalgia; 2022 Jul; 42(8):696-704. PubMed ID: 35302389
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
[TBL] [Abstract][Full Text] [Related]
9. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Lipton RB; Goadsby PJ; Smith J; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Cady R
Neurology; 2020 Mar; 94(13):e1365-e1377. PubMed ID: 32209650
[TBL] [Abstract][Full Text] [Related]
11. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
Pozo-Rosich P; Dodick DW; Ettrup A; Hirman J; Cady R
BMC Neurol; 2022 Oct; 22(1):394. PubMed ID: 36284281
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
Lipton RB; Charleston L; Tassorelli C; Brevig T; Hirman J; Cady R
J Headache Pain; 2022 Feb; 23(1):23. PubMed ID: 35130836
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
14. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
[TBL] [Abstract][Full Text] [Related]
15. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
Lipton RB; Dodick DW; Ailani J; McGill L; Hirman J; Cady R
Headache; 2021 May; 61(5):766-776. PubMed ID: 34013992
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
Smith TR; Spierings ELH; Cady R; Hirman J; Schaeffler B; Shen V; Sperling B; Brevig T; Josiassen MK; Brunner E; Honeywell L; Mehta L
J Headache Pain; 2021 Mar; 22(1):16. PubMed ID: 33781209
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
Smith TR; Spierings ELH; Cady R; Hirman J; Ettrup A; Shen V
J Headache Pain; 2021 Nov; 22(1):143. PubMed ID: 34823467
[TBL] [Abstract][Full Text] [Related]
18. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
Buse DC; Winner PK; Charleston L; Hirman J; Cady R; Brevig T
J Headache Pain; 2022 Feb; 23(1):29. PubMed ID: 35189811
[TBL] [Abstract][Full Text] [Related]
19. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
[TBL] [Abstract][Full Text] [Related]
20. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
Front Immunol; 2021; 12():765822. PubMed ID: 34759933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
